Orexo AB (ORX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -6.05% and Operating profit at -218.27% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

The company has declared Negative results for the last 3 consecutive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 1,000 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.71

Return on Equity

89.92%

Price to Book

-4.46

Revenue and Profits:

Net Sales:

118 Million

(Quarterly Results - Jun 2025)

Net Profit:

-40 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

57.32%

6 Months

54.57%

1 Year

12.27%

2 Years

174.14%

3 Years

7.39%

4 Years

-37.91%

5 Years

-67.84%

Orexo AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-6.05%

EBIT Growth (5y)

-218.27%

EBIT to Interest (avg)

-5.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.24

Sales to Capital Employed (avg)

1.45

Tax Ratio

4.95%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-6.70

EV to EBIT

-10.15

EV to EBITDA

456.81

EV to Capital Employed

9.70

EV to Sales

3.01

PEG Ratio

Dividend Yield

ROCE (Latest)

-95.64%

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -19.15% vs -8.80% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -150.31% vs 86.32% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "118.20",
          "val2": "146.20",
          "chgp": "-19.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.10",
          "val2": "11.50",
          "chgp": "-161.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.30",
          "val2": "14.10",
          "chgp": "-12.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.80",
          "val2": "-15.90",
          "chgp": "-150.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-156.50%",
          "val2": "2.70%",
          "chgp": "-15.92%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.64% vs 2.32% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -58.22% vs 27.76% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "590.00",
          "val2": "638.80",
          "chgp": "-7.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.50",
          "val2": "-45.60",
          "chgp": "123.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "60.00",
          "val2": "41.20",
          "chgp": "45.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-203.00",
          "val2": "-128.30",
          "chgp": "-58.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-302.90%",
          "val2": "-192.10%",
          "chgp": "-11.08%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

118.20

146.20

-19.15%

Operating Profit (PBDIT) excl Other Income

-7.10

11.50

-161.74%

Interest

12.30

14.10

-12.77%

Exceptional Items

0.00

Consolidate Net Profit

-39.80

-15.90

-150.31%

Operating Profit Margin (Excl OI)

-156.50%

2.70%

-15.92%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -19.15% vs -8.80% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -150.31% vs 86.32% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

590.00

638.80

-7.64%

Operating Profit (PBDIT) excl Other Income

10.50

-45.60

123.03%

Interest

60.00

41.20

45.63%

Exceptional Items

0.00

Consolidate Net Profit

-203.00

-128.30

-58.22%

Operating Profit Margin (Excl OI)

-302.90%

-192.10%

-11.08%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -7.64% vs 2.32% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -58.22% vs 27.76% in Dec 2023

All Annual Results

Company CV

About Orexo AB

Orexo AB

Pharmaceuticals & Biotechnology

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Company Coordinates

Company Details

Rapsgatan 7E , UPPSALA None : 754 50

Tel: 46 18 780880046 73 0641636

https://orexo.se/

Registrar Details